Integral Derivatives’s iShares Biotechnology ETF IBB Stock Holding History

Integral Derivatives’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-2,839	Closed	-$315K	–	823
2017 Q4	$303K	Sell	2,839 -17,900	-86%	-$1.91M	0.01%	868
2017 Q3	$2.31M	Buy	+20,739	New	+$2.22M	0.04%	274
2017 Q2	–	Sell	-15,378	Closed	-$1.51M	–	1173
2017 Q1	$1.5M	Buy	+15,378	New	+$1.47M	0.03%	396
2016 Q2	–	Sell	-4,263	Closed	-$382K	–	1018
2016 Q1	$371K	Buy	+4,263	New	+$381K	0.01%	593
2015 Q1	–	Sell	-2,793	Closed	-$308K	–	1230
2014 Q4	$282K	Buy	+2,793	New	+$271K	﹤0.01%	1107
2014 Q3	–	Sell	-21,093	Closed	-$1.81M	–	1457
2014 Q2	$1.81M	Buy	+21,093	New	+$1.66M	0.03%	468

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Natixis Paris, France $24.8B AUM 35.22% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Integral Derivatives's IBB Position: Q1 2018 in Review

Integral Derivatives sold out of iShares Biotechnology ETF (IBB) in Q1 2018, closing a stake of 2,839 shares — an estimated $315K sold.

Integral Derivatives first reported a position in IBB in Q2 2014 and held it in 6 quarters. The position peaked at $2.31M in Q3 2017. 608 funds tracked by Wall St. Rank hold IBB as of Q1 2018.

Integral Derivatives reported no remaining iShares Biotechnology ETF position as of Q1 2018 after selling out during the quarter.
Integral Derivatives sold 2,839 iShares Biotechnology ETF shares in Q1 2018, an estimated $315K.
Integral Derivatives first reported a position in iShares Biotechnology ETF in Q2 2014 and held it in 6 quarters.
Integral Derivatives's iShares Biotechnology ETF position peaked at $2.31M in Q3 2017.
608 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2018.

Based on Integral Derivatives's 13F filing for Q1 2018, filed 19 Apr 2018.